Adaptive Biotechnologies Corp has a consensus price target of $9.14 based on the ratings of 7 analysts. The high is $12 issued by Scotiabank on February 13, 2025. The low is $6 issued by JP Morgan on August 2, 2024. The 3 most-recent analyst ratings were released by Goldman Sachs, Piper Sandler, and Scotiabank on March 21, 2025, February 20, 2025, and February 13, 2025, respectively. With an average price target of $10.67 between Goldman Sachs, Piper Sandler, and Scotiabank, there's an implied 51.52% upside for Adaptive Biotechnologies Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/21/2025 | Buy Now | 27.84% | Goldman Sachs | Salveen Richter51% | $8 → $9 | Upgrade | Neutral → Buy | Get Alert |
02/20/2025 | Buy Now | 56.25% | Piper Sandler | David Westenberg59% | $7 → $11 | Reiterates | Overweight → Overweight | Get Alert |
02/13/2025 | Buy Now | 70.45% | Scotiabank | Sung Ji Nam45% | $10 → $12 | Maintains | Sector Outperform | Get Alert |
01/28/2025 | Buy Now | 6.53% | Goldman Sachs | Salveen Richter51% | $5.5 → $7.5 | Maintains | Neutral | Get Alert |
12/18/2024 | Buy Now | 27.84% | BTIG | Mark Massaro69% | $8 → $9 | Maintains | Buy | Get Alert |
11/11/2024 | Buy Now | -0.57% | Piper Sandler | David Westenberg59% | $6 → $7 | Maintains | Overweight | Get Alert |
10/02/2024 | Buy Now | 13.64% | BTIG | Mark Massaro69% | $7 → $8 | Maintains | Buy | Get Alert |
08/02/2024 | Buy Now | -14.77% | JP Morgan | Rachel Vatnsdal62% | $5 → $6 | Maintains | Overweight | Get Alert |
05/08/2024 | Buy Now | -28.98% | JP Morgan | Rachel Vatnsdal62% | $8 → $5 | Maintains | Overweight | Get Alert |
04/04/2024 | Buy Now | -28.98% | BTIG | Mark Massaro69% | $6 → $5 | Maintains | Buy | Get Alert |
02/16/2024 | Buy Now | -28.98% | Goldman Sachs | Salveen Richter51% | $11 → $5 | Maintains | Neutral | Get Alert |
02/15/2024 | Buy Now | 13.64% | JP Morgan | Rachel Vatnsdal62% | $11 → $8 | Maintains | Overweight | Get Alert |
11/13/2023 | Buy Now | -14.77% | Piper Sandler | David Westenberg59% | $13 → $6 | Maintains | Overweight | Get Alert |
11/10/2023 | Buy Now | 56.25% | JP Morgan | Rachel Vatnsdal62% | $12 → $11 | Maintains | Overweight | Get Alert |
10/24/2023 | Buy Now | 42.05% | Morgan Stanley | Tejas Savant50% | $13 → $10 | Maintains | Equal-Weight | Get Alert |
10/16/2023 | Buy Now | 84.66% | Piper Sandler | David Westenberg59% | $14 → $13 | Maintains | Overweight | Get Alert |
08/08/2023 | Buy Now | 98.86% | Piper Sandler | David Westenberg59% | $15 → $14 | Maintains | Overweight | Get Alert |
08/04/2023 | Buy Now | 84.66% | Morgan Stanley | Tejas Savant50% | $14 → $13 | Maintains | Equal-Weight | Get Alert |
05/05/2023 | Buy Now | 98.86% | Morgan Stanley | Tejas Savant50% | $15 → $14 | Maintains | Equal-Weight | Get Alert |
02/16/2023 | Buy Now | 113.07% | Morgan Stanley | Tejas Savant50% | $16 → $15 | Maintains | Equal-Weight | Get Alert |
02/15/2023 | Buy Now | -0.57% | Credit Suisse | Dan Leonard56% | → $7 | Reiterates | → Underperform | Get Alert |
01/05/2023 | Buy Now | 113.07% | Scotiabank | Sung Ji Nam45% | → $15 | Initiates | → Sector Outperform | Get Alert |
12/21/2022 | Buy Now | 98.86% | Piper Sandler | David Westenberg59% | $7.5 → $14 | Upgrade | Neutral → Overweight | Get Alert |
11/07/2022 | Buy Now | 127.27% | Morgan Stanley | Tejas Savant50% | $17 → $16 | Maintains | Equal-Weight | Get Alert |
10/26/2022 | Buy Now | 6.53% | Piper Sandler | David Westenberg59% | $12 → $7.5 | Maintains | Neutral | Get Alert |
08/25/2022 | Buy Now | 13.64% | Credit Suisse | Dan Leonard56% | → $8 | Initiates | → Underperform | Get Alert |
08/17/2022 | Buy Now | 70.45% | Piper Sandler | David Westenberg59% | $7.5 → $12 | Maintains | Neutral | Get Alert |
06/03/2022 | Buy Now | 6.53% | Piper Sandler | David Westenberg59% | → $7.5 | Initiates | → Neutral | Get Alert |
05/24/2022 | Buy Now | 42.05% | Goldman Sachs | Salveen Richter51% | $14 → $10 | Maintains | Neutral | Get Alert |
05/06/2022 | Buy Now | 155.68% | Morgan Stanley | Tejas Savant50% | $27 → $18 | Maintains | Equal-Weight | Get Alert |
The latest price target for Adaptive Biotechnologies (NASDAQ:ADPT) was reported by Goldman Sachs on March 21, 2025. The analyst firm set a price target for $9.00 expecting ADPT to rise to within 12 months (a possible 27.84% upside). 9 analyst firms have reported ratings in the last year.
The latest analyst rating for Adaptive Biotechnologies (NASDAQ:ADPT) was provided by Goldman Sachs, and Adaptive Biotechnologies upgraded their buy rating.
The last upgrade for Adaptive Biotechnologies Corp happened on March 21, 2025 when Goldman Sachs raised their price target to $9. Goldman Sachs previously had a neutral for Adaptive Biotechnologies Corp.
There is no last downgrade for Adaptive Biotechnologies.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptive Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptive Biotechnologies was filed on March 21, 2025 so you should expect the next rating to be made available sometime around March 21, 2026.
While ratings are subjective and will change, the latest Adaptive Biotechnologies (ADPT) rating was a upgraded with a price target of $8.00 to $9.00. The current price Adaptive Biotechnologies (ADPT) is trading at is $7.04, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.